What Is Long COVID and Why Does It Persist for Years?
Long COVID affects hundreds of millions worldwide, with symptoms lasting months or years after infection. Scientists have identified viral persistence, autoantibodies, and immune exhaustion as key drivers—and new treatments are finally emerging.
A Lingering Legacy of the Pandemic
Years after the acute phase of the COVID-19 pandemic, a quieter crisis continues. Long COVID—a condition in which symptoms persist for weeks, months, or even years after the initial SARS-CoV-2 infection—affects an estimated 36% of people who contract the virus, according to a meta-analysis of 429 studies published in Open Forum Infectious Diseases. By some estimates, more than 400 million people worldwide have experienced or are experiencing it.
Symptoms range from debilitating fatigue and brain fog to heart palpitations, joint pain, and breathing difficulties. For many patients, the condition upends careers, relationships, and daily life. But after years of uncertainty, scientists are finally zeroing in on the biological mechanisms—and potential treatments.
Three Mechanisms Driving the Disease
Researchers have identified several overlapping pathways that explain why Long COVID lingers. No single mechanism accounts for every case, which is part of what makes it so difficult to diagnose and treat.
Viral Persistence
One of the most significant breakthroughs has been confirming that SARS-CoV-2 can hide in the body long after the acute infection clears. Highly sensitive tissue biopsies have found viral RNA or protein fragments lurking in the gut lining, lymph nodes, and potentially the central nervous system—sometimes up to two years after the original illness. These viral reservoirs may continuously trigger low-grade inflammation, keeping the immune system in a state of alert.
Autoantibodies Gone Rogue
A growing body of evidence points to autoimmunity as a central driver. Research coordinated by UMC Utrecht and Amsterdam UMC provided some of the strongest functional evidence yet: when scientists injected IgG antibodies from Long COVID patients into mice, the animals developed persistent pain-like hypersensitivity lasting at least two weeks. In other words, the patients' own antibodies were attacking their bodies. Distinct patient subgroups show unique autoantibody profiles, supporting the view that Long COVID is not one disease but several.
Immune Exhaustion
A 2026 study in Nature Immunology found that Long COVID activates both pro-inflammatory and immune exhaustion pathways simultaneously. The immune system is caught in a paradox—overreacting in some ways while becoming depleted in others. Reactivation of dormant viruses like Epstein-Barr virus during this period of immune confusion may compound symptoms further.
Who Is Most at Risk?
Long COVID does not strike everyone equally. Women are disproportionately affected, with an estimated prevalence of 45% compared to 37% in men. Geographic variation is also notable: South America reports the highest rates at 51%, followed by Europe at 39% and North America at 30%. Children and adolescents appear somewhat protected, with a prevalence of about 23% compared to 35% in adults.
Severe initial infection, pre-existing conditions like diabetes and obesity, and lack of vaccination all increase risk—though even mild cases can trigger lasting symptoms.
New Treatments on the Horizon
With mechanisms now better understood, targeted therapies are entering clinical trials. The NIH's RECOVER-TLC program is testing baricitinib (an anti-inflammatory), low-dose naltrexone, and semaglutide (a GLP-1 agonist that may help reset metabolic dysfunction behind brain fog). Extended antiviral courses of 15 to 30 days—far longer than the standard five—are being explored to clear persistent viral reservoirs.
For autoantibody-driven cases, therapies like immunoadsorption and plasmapheresis, which filter harmful antibodies from the blood, show early promise. The challenge is matching each patient to the right treatment based on their specific biological subtype.
A Long Road Ahead
Long COVID remains one of the largest mass-disabling events in modern history. While breakthroughs in understanding its mechanisms offer genuine hope, millions of patients still lack effective treatment. As research accelerates, the biggest shift may be recognizing Long COVID not as a single condition but as a spectrum of post-infectious syndromes—each requiring its own therapeutic approach.
